312 related articles for article (PubMed ID: 26873681)
1. Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.
Böhm M; Robertson M; Borer J; Ford I; Komajda M; Mahfoud F; Ewen S; Swedberg K; Tavazzi L
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873681
[TBL] [Abstract][Full Text] [Related]
2. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study.
Böhm M; Borer J; Ford I; Gonzalez-Juanatey JR; Komajda M; Lopez-Sendon J; Reil JC; Swedberg K; Tavazzi L
Clin Res Cardiol; 2013 Jan; 102(1):11-22. PubMed ID: 22575988
[TBL] [Abstract][Full Text] [Related]
3. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
4. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.
Komajda M; Böhm M; Borer JS; Ford I; Robertson M; Manolis AJ; Tavazzi L; Swedberg K;
Eur J Heart Fail; 2014 Jul; 16(7):810-6. PubMed ID: 24961493
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
[No Abstract] [Full Text] [Related]
7. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.
Böhm M; Schumacher H; Leong D; Mancia G; Unger T; Schmieder R; Custodis F; Diener HC; Laufs U; Lonn E; Sliwa K; Teo K; Fagard R; Redon J; Sleight P; Anderson C; O'Donnell M; Yusuf S
Hypertension; 2015 Mar; 65(3):651-61. PubMed ID: 25583157
[TBL] [Abstract][Full Text] [Related]
8. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
[TBL] [Abstract][Full Text] [Related]
10. Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction.
Böhm M; Abdin A; Slawik J; Mahfoud F; Borer J; Ford I; Swedberg K; Tavazzi L; Batailler C; Komajda M
Eur J Heart Fail; 2023 Aug; 25(8):1429-1435. PubMed ID: 37092340
[TBL] [Abstract][Full Text] [Related]
11. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
[TBL] [Abstract][Full Text] [Related]
12. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.
Böhm M; Lloyd SM; Ford I; Borer JS; Ewen S; Laufs U; Mahfoud F; Lopez-Sendon J; Ponikowski P; Tavazzi L; Swedberg K; Komajda M
Eur J Heart Fail; 2016 Jun; 18(6):672-83. PubMed ID: 26952245
[TBL] [Abstract][Full Text] [Related]
13. Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure.
Reil JC; Robertson M; Ford I; Borer J; Komajda M; Swedberg K; Tavazzi L; Böhm M
Eur J Heart Fail; 2013 Sep; 15(9):1044-52. PubMed ID: 23696612
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
Bouabdallaoui N; O'Meara E; Bernier V; Komajda M; Swedberg K; Tavazzi L; Borer JS; Bohm M; Ford I; Tardif JC
ESC Heart Fail; 2019 Dec; 6(6):1199-1207. PubMed ID: 31591826
[TBL] [Abstract][Full Text] [Related]
15. Heart rate and its reduction in chronic heart failure and beyond.
Nikolovska Vukadinović A; Vukadinović D; Borer J; Cowie M; Komajda M; Lainscak M; Swedberg K; Böhm M
Eur J Heart Fail; 2017 Oct; 19(10):1230-1241. PubMed ID: 28627045
[TBL] [Abstract][Full Text] [Related]
16. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure - J-SHIFT Study.
Tsutsui H; Momomura SI; Yamashina A; Shimokawa H; Kihara Y; Saito Y; Hagiwara N; Ito H; Yano M; Yamamoto K; Ako J; Inomata T; Sakata Y; Tanaka T; Kawasaki Y;
Circ J; 2019 Sep; 83(10):2049-2060. PubMed ID: 31391387
[TBL] [Abstract][Full Text] [Related]
18. Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function.
McCullough PA; Barnard D; Clare R; Ellis SJ; Fleg JL; Fonarow GC; Franklin BA; Kilpatrick RD; Kitzman DW; O'Connor CM; Piña IL; Thadani U; Thohan V; Whellan DJ;
Clin Cardiol; 2013 Oct; 36(10):611-20. PubMed ID: 23929781
[TBL] [Abstract][Full Text] [Related]
19. Clinical Experience with Ivabradine in Acute Heart Failure.
Pascual Izco M; Alonso Salinas GL; Sanmartín Fernández M; Del Castillo Carnevalli H; Jiménez Mena M; Camino López A; Zamorano Gómez JL
Cardiology; 2016; 134(3):372-4. PubMed ID: 27100325
[TBL] [Abstract][Full Text] [Related]
20. Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF.
Cotter G; Davison BA; Butler J; Collins SP; Ezekowitz JA; Felker GM; Filippatos G; Levy PD; Metra M; Ponikowski P; Teerlink JR; Voors AA; Senger S; Bharucha D; Goin K; Soergel DG; Pang PS
Clin Res Cardiol; 2018 Feb; 107(2):170-181. PubMed ID: 28986703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
